WO2000053614A1 - Verfahren zur herstellung von glycokonjugaten von 20(s)-camptothecin - Google Patents
Verfahren zur herstellung von glycokonjugaten von 20(s)-camptothecin Download PDFInfo
- Publication number
- WO2000053614A1 WO2000053614A1 PCT/EP2000/001480 EP0001480W WO0053614A1 WO 2000053614 A1 WO2000053614 A1 WO 2000053614A1 EP 0001480 W EP0001480 W EP 0001480W WO 0053614 A1 WO0053614 A1 WO 0053614A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- camptothecin
- amino acid
- acid
- compounds
- Prior art date
Links
- 0 C*(c(cccc1)c1I=C1C*2C3=O)=C1C2=CC([C@@]1(*)CN)=*3IOC1=O Chemical compound C*(c(cccc1)c1I=C1C*2C3=O)=C1C2=CC([C@@]1(*)CN)=*3IOC1=O 0.000 description 1
- AWUUPYNOGKSJFE-RJJUWVFESA-N C[C@@H]([C@H]([C@H]([C@@H]1O)OC)O)O[C@@H]1Oc(cc1)ccc1NC(N[C@@H](Cc1c[nH]cn1)C(O)=O)=S Chemical compound C[C@@H]([C@H]([C@H]([C@@H]1O)OC)O)O[C@@H]1Oc(cc1)ccc1NC(N[C@@H](Cc1c[nH]cn1)C(O)=O)=S AWUUPYNOGKSJFE-RJJUWVFESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a process for the preparation of glycoconjugates of 20 (S) -camptothecin, in which a 3-O-methylated ⁇ -L-fucose
- Building block is linked via thiourea-modified peptide spacer to the 20-hydroxyl group of a camptothecin derivative.
- camptothecin derivatives About 20 years later it was found that the biological activity is due to enzyme inhibition of topoisomerase I. Since then, research activities have been intensified again in order to find more tolerable and in vivo effective camptothecin derivatives.
- WO 9631532 describes sugar-modified cytostatics and processes for their production, in which the linking of various cytotoxic or cytostatically active compounds with e.g. Regioselectively modified carbohydrate building blocks leads to an improvement in tumor selectivity via certain spacers.
- WO 9851703 describes specific glycoconjugates of 20 (S) -camptothecin of the formula (I) and processes for their preparation:
- R 1 stands for a sterically demanding non-polar side chain of an amino acid
- R 2 represents a basic side chain of an amino acid. It was surprisingly found that the special structure of the camptothecin derivatives described there, namely the attachment of ⁇ -L-fucose units modified in the 3-position via a thiourea-modified peptide spacer, consisting of a sterically demanding non-polar and a basic amino acid the
- 20-hydroxyl group of 20 (S) -camptothecin leads to very particularly preferred conjugates, which have a particularly high stability, better water solubility, higher tolerance, greater therapeutic effectiveness against various tumors both in vitro and in vivo compared to the previously known compounds and a significantly higher tumor selectivity especially with regard to
- WO 9851703 describes two processes for the preparation of the compounds of the formula (I).
- the glycoconjugates of the formula (I) according to the invention are converted into a peptidyl camptothecin of the formula (III) by sequential linking of 20 (S) -camptothecin with two corresponding amino acids via a peptidyl-camptothecin of the formula (II) and subsequent binding of the isothiocyanate of the formula (IV) prepared (linear synthesis):
- the key step in the second process is to couple the building blocks
- the carboxyl group of the building block (V) is activated and then reacted with the free amino group of the building block (II).
- the coupling reagents known in peptide chemistry are used for the activation of the carboxyl group, such as those e.g. in Jakubke / Jeschkeit: amino acids, peptides, proteins; Verlag Chemie 1982 or
- Examples include N-carboxylic acid anhydrides, acid chlorides or mixed anhydrides, adducts with carbodimides e.g. N, N'-diethyl, N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide, N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride, N-cyclohexyl-N '- (2- mo holinoethyl) carbodiimide metho-p-toluenesulfonate, or carbonyl compounds such as carbonyldiimidazole, or 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-1, 2-oxazolium-3-sulfate or 2-tert-butyl- 5-methyl-isoxazolium perchlorate, or acyla
- carbodimides e.g. N, N'-
- the present invention thus relates to a process for the preparation of compounds of the formula (I)
- R 1 stands for a sterically demanding non-polar side chain of an amino acid
- R 2 represents a basic side chain of an amino acid.
- R 2 has the meaning given above, converted to an amino acid conjugate of the formula (V),
- R 2 has the meaning given above
- R 1 has the meaning given above
- the side chain protecting group is split off and the compounds are optionally converted into a suitable salt
- the coupling of the building blocks (II) and (V) is carried out in the presence of a coupling reagent that is selected from the group consisting of the following compounds:
- R 1 represents a branched alkyl radical having up to 4 carbon atoms and R 2 represents a radical of the formula - (CH 2 ) n -R 3 , where
- n stands for a number from 1 to 4.
- Target compound (I) are made.
- the individual steps of the above production process according to the invention can be carried out in suitable solvents such as dimethylformamide at various pressure and temperature ratios, for example 0.5 to 2 bar and preferably under normal pressure, or -30 to + 100 ° C. and preferably -10 to + 80 ° C. (DMF), tetrahydrofuran (THF), dichloromethane, chloroform, lower alcohols, acetonitrile, dioxane, water or in mixtures of the solvents mentioned.
- suitable solvents such as dimethylformamide at various pressure and temperature ratios, for example 0.5 to 2 bar and preferably under normal pressure, or -30 to + 100 ° C. and preferably -10 to + 80 ° C. (DMF), tetrahydrofuran (THF), dichloromethane, chloroform, lower alcohols, acetonitrile, dioxane, water or in mixtures of the solvents mentioned.
- suitable solvents such as dimethylformamide at various pressure and temperature ratios, for example
- the isothiocyanate of the formula (IV) serving as the starting compound can be obtained, for example, according to the process described in WO 98/51703 from commercially available p-nitrophenyl- ⁇ -L-fucopyranoside by selective etherification of the hydroxy group in the 3-position of the saccharide residue with methyl iodide and dibutyl tin oxide, reduction of the nitro group by means of catalytic hydrogenation and subsequent reaction with a thiocarbonic acid derivative such as thio phosgene or thiocarbonyl-bisimidazole can be prepared in the presence of a base such as ethyldiisopropylamine.
- a base such as ethyldiisopropylamine.
- Adducts with carbodiimides e.g. N, N'-diethyl, N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide, N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride, N-cyclohexyl-N '- ( 2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate or carbonyl compounds such as carbonyldumidazole, or 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-1, 2-oxazolium-3-sulfate or 2-tert-butyl- 5-methyl-isoxazolium perchlorate, or acylamino compounds such as 2-ethoxy-l-ethoxycarbonyl-l, 2-di-hydroquinoline, or propanephosphonic anhydride, or isobutyl
- amino acid component can also be used in the form of a Leuchs anhydride. This type of amino acid activation is preferred for the acylation of 20 (S) -camptothecin with amino acid components.
- N - [(Dimethylamino) -1H-1,2,3-triazolo [4,5-pyyridine-1-ylmethylene] -N-methylmethanaminium hexafluorophosphate-N-oxide (HATU) is particularly preferably used as coupling reagent:
- HATU can be obtained from Perseptive Biosystems GmbH, Wiesbaden, Germany.
- Bases which can be used in the individual steps of the production process according to the invention are, for example, triethylamine, ethyldiisopropylamine, pyridine, N, N-dimethylaminopyridine or other bases conventionally used in such steps.
- the protective groups known in peptide chemistry for example of the urethane, alkyl, acyl, ester or amide type, can be used as protective groups for third-party functions of the amino acids.
- benzyloxycarbonyl 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 2-nitro-
- Protective groups can be split off in corresponding reaction steps, for example by exposure to acid or base, hydrogenolytically or in some other way reductively.
- camptothecin building block used as the starting compound can be present in the 20 (R) or in the 20 (S) configuration or as a mixture of these two steroisomeric forms.
- the 20 (S) configuration is preferred.
- Amino acids with "sterically demanding” side chains are understood to mean those amino acids whose side chain has a branch in the ⁇ or ⁇ position; valine and isoleucine or leucine may be mentioned as examples.
- amino acids with basic side chains are: lysine, arginine, histidine, ornithine, diaminobutyric acid.
- the compounds according to the invention are preferably in the form of their salts.
- salts with organic or inorganic acids may be mentioned here. These salts can be prepared by reacting the free compounds of the formula (I) with organic or inorganic acids.
- the preferred acids here are hydrohalic acids, e.g. hydrochloric acid and hydrobromic acid, especially hydrochloric acid, also phosphoric acid, nitric acid, sulfuric acid, mono- and bifunctional carboxylic acids and hydroxycarboxylic acids, e.g. Acetic acid, trifluoroacetic acid, maleic acid, malonic acid, oxalic acid, gluconic acid, succinic acid,
- sulfonic acids such as p-toluenesulfonic acid, 1, 5-naphthalenedisulfonic acid or camphorsulfonic acid in question.
- the present invention is illustrated below by way of non-limiting examples and comparative examples.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002366632A CA2366632A1 (en) | 1999-03-06 | 2000-02-23 | Method for producing glyco-conjugates of 20(s)-camptothecin |
EP00909241A EP1173454A1 (de) | 1999-03-06 | 2000-02-23 | Verfahren zur herstellung von glycokonjugaten von 20(s)-camptothecin |
AU31595/00A AU3159500A (en) | 1999-03-06 | 2000-02-23 | Method for producing glyco-conjugates of 20(s)-camptothecin |
JP2000604049A JP2002539132A (ja) | 1999-03-06 | 2000-02-23 | 20(s)−カンプトテシンの糖−共役体の製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19909979.0 | 1999-03-06 | ||
DE19909979A DE19909979A1 (de) | 1999-03-06 | 1999-03-06 | Verfahren zur Herstellung von Glycokonjugaten von 20(S)-Camptothecin |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000053614A1 true WO2000053614A1 (de) | 2000-09-14 |
WO2000053614A8 WO2000053614A8 (de) | 2002-01-24 |
Family
ID=7899996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/001480 WO2000053614A1 (de) | 1999-03-06 | 2000-02-23 | Verfahren zur herstellung von glycokonjugaten von 20(s)-camptothecin |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1173454A1 (de) |
JP (1) | JP2002539132A (de) |
AU (1) | AU3159500A (de) |
CA (1) | CA2366632A1 (de) |
DE (1) | DE19909979A1 (de) |
WO (1) | WO2000053614A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
US10046068B2 (en) | 2013-03-15 | 2018-08-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Saccharide conjugates |
US9919055B2 (en) | 2013-03-15 | 2018-03-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Sugar-linker-drug conjugates |
JP2021095424A (ja) * | 2018-03-28 | 2021-06-24 | 持田製薬株式会社 | 抗癌剤結合アルギン酸誘導体 |
WO2020156189A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川科伦博泰生物医药股份有限公司 | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051703A1 (de) * | 1997-05-14 | 1998-11-19 | Bayer Aktiengesellschaft | Glycokonjugate von 20(s)-camptothecin |
-
1999
- 1999-03-06 DE DE19909979A patent/DE19909979A1/de not_active Withdrawn
-
2000
- 2000-02-23 AU AU31595/00A patent/AU3159500A/en not_active Abandoned
- 2000-02-23 CA CA002366632A patent/CA2366632A1/en not_active Abandoned
- 2000-02-23 JP JP2000604049A patent/JP2002539132A/ja active Pending
- 2000-02-23 WO PCT/EP2000/001480 patent/WO2000053614A1/de not_active Application Discontinuation
- 2000-02-23 EP EP00909241A patent/EP1173454A1/de not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051703A1 (de) * | 1997-05-14 | 1998-11-19 | Bayer Aktiengesellschaft | Glycokonjugate von 20(s)-camptothecin |
Also Published As
Publication number | Publication date |
---|---|
DE19909979A1 (de) | 2000-09-07 |
AU3159500A (en) | 2000-09-28 |
CA2366632A1 (en) | 2000-09-14 |
WO2000053614A8 (de) | 2002-01-24 |
EP1173454A1 (de) | 2002-01-23 |
JP2002539132A (ja) | 2002-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0939765B1 (de) | Glycokonjugate von modifizierten camptothecin-derivaten(a- oder b-ring-verknüpfung) | |
EP0300969B1 (de) | Polyethylenglykolcarbaminate | |
EP0934329B1 (de) | Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung) | |
EP0981542B1 (de) | Glycokonjugate von 20(s)-camptothecin | |
DE19512484A1 (de) | Kohlenhydratmodifizierte Cytostatika | |
DE3044740C2 (de) | ||
WO1998015571A1 (de) | Modifizierte cytostatika | |
DE69922378T2 (de) | Oxidierte sulfurierte distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
WO2000053614A1 (de) | Verfahren zur herstellung von glycokonjugaten von 20(s)-camptothecin | |
DE69828780T2 (de) | Amidinocamptpthecin-derivate | |
EP2051992B1 (de) | Verfahren zur herstellung von kondensationsprodukten aus n-substituierten glycinderivaten (peptoide) über sequentielle ugi-mehrkomponentenreaktionen | |
EP1603930B1 (de) | Proteinbindende derivate von platinkomplexen mit cyclobutan-1,1-dicarboxylatliganden | |
DE1163337B (de) | Verfahren zur Herstellung von Trihydroxamsaeuren | |
WO2001058932A1 (de) | Glycokonjugate von cytostatika | |
DE10005275A9 (de) | Neuartige glycokonjugate | |
DE19643764A1 (de) | Glycokonjugate von modifizierten Camptothecin-Derivaten (20-0-Verknüpfung) | |
WO1998015573A1 (de) | 20-o-verknüpfte glycokonjugate von camptothecin | |
DE1805280C3 (de) | Verfahren zur Herstellung von Cyclopeptiden, bestimmte Cyclopeptide und diese enthaltende pharmazeutische Zusammensetzungen | |
EP0501250A1 (de) | Fucose-markierte Batracylinderivate | |
DE2725732C2 (de) | Bestatin-Analoga, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate | |
DE19801037A1 (de) | Glycokonjugate von 20(S)-Camptothecin | |
EP0054514A1 (de) | Neue antibiotisch wirksame Aminopapulacandin-Derivate | |
AT354657B (de) | Verfahren zur herstellung von neuen dipeptid- -derivaten | |
DE19813137A1 (de) | Glycokonjugate von 20(S)-Camptothecin | |
DE2527901A1 (de) | Verfahren zur herstellung von neuen benzodiazepinderivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000909241 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2366632 Country of ref document: CA Ref country code: CA Ref document number: 2366632 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 604049 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914633 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000909241 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000909241 Country of ref document: EP |